Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD.
about
Safety concerns about intravenous iron therapy in patients with chronic kidney diseaseA randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.The Prevalence and Management of Anemia in Chronic Kidney Disease Patients: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).Comparison of short-term efficacy of iron sucrose with those of ferric chloride in hemodialysis patients: An open-label study.The Strategy to Prevent and Regress the Vascular Calcification in Dialysis Patients.The Labile Side of Iron Supplementation in CKDPerformance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations.Overview of iron metabolism in health and disease.Sirt1 Inhibits Oxidative Stress in Vascular Endothelial Cells.Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.Cellular senescence, senescence-associated secretory phenotype, and chronic kidney diseaseComplexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis.The safety of available treatment options for iron-deficiency anemia.Iron suppresses erythropoietin expression via oxidative stress-dependent hypoxia-inducible factor-2 alpha inactivation.
P2860
Q26764881-F829B9AD-85CD-4852-86CF-2F3B9BB300FEQ35998091-2D5E8DFB-1AC6-4E14-8205-0F92C6A5BE38Q37570176-93CA1D40-58E5-4E37-8A2D-03B88033BAC8Q37593694-06762951-3A1C-4A4F-B443-43AF736322FFQ37670856-89D0AECA-42F5-4C07-B549-9E89C0652E41Q38496987-E298C1E0-C6E3-412E-AB16-D9F3B45BBCA6Q38761669-26176BFD-CD72-485B-ADCA-118E6AB7C59DQ39179833-86520EB0-73DC-41B9-ACE5-87370EDD3871Q39331686-87A85C5A-C955-49A4-91BD-1B478FBA828EQ40469488-ADC4F8E4-97F3-4D45-A7D6-A948957D7226Q42031434-05C9303B-0A99-4909-84F1-2FC16F5B6B07Q47805747-EC104F2E-280E-4E1B-B50D-82AFB48612C8Q48086832-E69C848F-E505-4E84-93CC-F4A0C0A92C96Q48548255-A051671D-7BEF-4222-8A63-6CA0AB3A526AQ51109964-B40457C5-6FE1-442F-AE66-A60A3B9DCE51
P2860
Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Iron sucrose accelerates early ...... ing adhesion molecules in CKD.
@ast
Iron sucrose accelerates early ...... ing adhesion molecules in CKD.
@en
Iron sucrose accelerates early ...... ing adhesion molecules in CKD.
@nl
type
label
Iron sucrose accelerates early ...... ing adhesion molecules in CKD.
@ast
Iron sucrose accelerates early ...... ing adhesion molecules in CKD.
@en
Iron sucrose accelerates early ...... ing adhesion molecules in CKD.
@nl
prefLabel
Iron sucrose accelerates early ...... ing adhesion molecules in CKD.
@ast
Iron sucrose accelerates early ...... ing adhesion molecules in CKD.
@en
Iron sucrose accelerates early ...... ing adhesion molecules in CKD.
@nl
P2093
P2860
P356
P1476
Iron sucrose accelerates early ...... ting adhesion molecules in CKD
@en
P2093
Der-Cherng Tarng
Ko-Lin Kuo
Szu-Chun Hung
P2860
P304
P356
10.1681/ASN.2013080838
P577
2014-04-10T00:00:00Z